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auto-HCT for AL. (Leung N et al. Blood 2005;106:3353-3357)
Methods: We performed a retrospective chart review to
identify patients with excessive weight gain while under-
going ﬁlgrastim-induced PBSC mobilization. The primary
endpointwas todetermine the incidence of> 2% bodyweight
gain during PBSC mobilization. Secondary endpoints were to
identify the factors that predict abnormal weight gain and to
evaluate its impact on NRM and OS after auto-HCT.
Results: We identiﬁed 95 patients with AL who underwent
PBSC mobilization and collection followed by auto-HCT
between 2002 and 2011. Thirty-nine (41%) patients had renal
involvement, 12 patients had cardiac involvement (12.6%)
and 5 (5.2%) patients had liver involvement. Seven patients
required hospitalization during PBSC mobilization due to
ﬂuid overload. Six patients died within a year of auto-HCT
non-relapse causes with 1-year NRM of 6.3%. Median follow
up after auto-HCT in surviving patients was 13 months.
Kaplan-Meier estimates of median OS was 73 months. Forty-
nine (51.5%) patients had >2% weight gain due to ﬂuid
overload during PBSCmobilization, while 46 patients (48.5%)
had 2 % weight gain. More patients with >2% weight gain
required diuretics (34 vs. 10: P < .0001) and had lower
median serum albumin (2.8 vs. 3.75 g/dl, P < 0.0001). There
were no signiﬁcant differences in baseline serum creatinine,
GFR, alkaline phosphatase, ﬁlgrastim dose, urine total
protein, BNP, ejection fraction, cardiac septal thickness,
number of organs involved, or cardiac or renal involvement
between the two groups. 1-year NRM was 6.1 vs. 8.6 % in
patients with >2% or 2% weight gain (p¼0.70). There was
no signiﬁcant difference in median OS survival between
patients with > or 2% weight gain (p¼0.54: Figure 1).
Conclusion: Patients with AL and low baseline serum
albumin are at higher risk of ﬂuid retention and excessive
weight gain that may require hospitalization. However, in
our study, this weight gain did not have an adverse impact on
NRM or OS.Figure 1.139
Successful Stem Cell Mobilisation with Plerixafor in
a Patient with Multiple Myeloma and Dialysis-Dependant
Renal Failure
Karim Ibrahim, John Moore, Annabel Horne. St. Vincent's
Hospital, Darlinghurst NSW, Australia
The aim of this case report is to describe the use of plerixafor
in a patient with multiple myeloma and dialysis-dependantrenal failure. A 43-year-old man with multiple myeloma and
dialysis-dependent renal failure was evaluated for an autol-
ogous stem cell transplant (ASCT). Following Stem cell
mobilisation with cyclophosphamide 1.5g/m2 and 9 doses of
granulocyte colony-stimulating factor (G-CSF) 10mcg/kg/day
the patient's pre apheresis CD34+ count was inadequate at
2.18 cells/mL. Perixafor was prescribed to achieve stem cell
mobilisation. There is no dose recommendation for plerixafor
in patients with CrCl< 20mL/min or those on dialysis. In this
patient we used 0.16mg/kg/day dose, which is the dose rec-
ommended for patients with CrCl 20-50mL/min. The ﬁrst
plerixafor dose was given subcutaneously post-dialysis 8
hours before apheresis and the second dose was given the
next day 9 hours prior to second apheresis session. The pre-
apheresis CD34+ countwas 11.99 and8.82 cells/mLwith a total
White cell count of 22.2 and 17.3 x 10^9/L after the ﬁrst and
second doses respectively. The patient underwent stem cell
collectionvia the SpectraOptia cell separatorwith a total yield
of 2.4 x 106 cells/kg. There were no observed toxicities with
plerixafor. InMay 2012, 6weeks after stem cell collection, the
patient underwent ASCT with reduced dose of Melphalan
140mg/m2. Neutrophil engraftment occurred at day +11, the
patientwasdischarged at day+16. Todate thepatient remains
well and in remission. This case report illustrates that pler-
ixafor can safely and effectively be used to mobilise adequate
stem cells in multiple myeloma patients with end stage renal
failure. Information regarding dosing and safety of plerixafor
in dialysis patients remains limited,wehope that information
provided by this report would be useful for other clinicians
who are considering the use of plerixafor in this setting.141
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Successful Autologous Peripheral Blood Stem Cell
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Toshiya Kagoo, Mie Yoneda, Ryusuke Yamamoto, Kota Ohashi,
Toru Hosoda, Akihiro Yokoyama, Saigen Boku, Hironori Ueno,
Takahiro Yano. Division of Hematology, Department of Internal
Medicine, National Hospital Organization Tokyo Medical
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Autologous stem cell transplantationplays a critical role in the
management of patients with hematologic malignancies
such as multiple myeloma and malignant lymphoma. The
minimum number of CD34 positive cells required for trans-
plantation is believed to be 2.0106 cells/kg. Up to 20% of the
patients, however, fail to reach the number after a single
collection attempt and require multiple aphereses to obtain
a sufﬁcient number of stem cells. To predict the outcome of
mobilization, several pre-mobilization factors have been
investigated, including peripheral blood CD34+ cell count at
the time of harvest, but little is as yet known about the
signiﬁcance of serum lactate dehydrogenase (LDH). We,
therefore, sought to evaluate the predictive potential of serum
LDH for the autologous stem cell yield. Peripheral blood stem
cell mobilization attempts were made from April 2002 to
March 2012 for 55 consecutive patients of hematologic
disorders. Primary diagnosis of our patients and their mobi-
lization chemotherapy regimens are shown in Table 1. All
patient received G-CSF (ﬁlgrastim 400mg/sq/day or lenogras-
tim 10mg/kg/day subcutaneously). None was mobilized with
G-CSF alone. Aphereseswere repeated until the total stem cell
yield exceeded 2106cells/kg, for maximum 3 consecutive
days. Forty-four patients successfully produced the sufﬁcient
numberof stemcells,while 11patients failed (poormobilizer).
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in pre-mobilization WBC counts and serum LDH levels.
However, the ratio of the LDH level immediately before
apheresis to the lowest one (“LDH-ratio”) were signiﬁcantly
lower in poor mobilizers than good mobilizers. Our ROC
analysis showed that the cut-off value of “LDH-ratio”was 1.75.
An elevation of serum LDH levels to reach “LDH-ratio”>1.75
were found to be a useful predictive factor for successful
CD34+ stem cell collection. The delay in reaching “LDH-
ratio”>1.75 may suggest that we should modify the mobili-
zation regimen by, for instance, adding prelixafor.Table 1
Pts’ characteristics
No. of Patients 55
Median age (range) 56(35-69)
Gender, male (%) 31(56)
Primary Disease
MM 19
NHL 26
HL 4
Others 6
Median WBC counts 103/mL (range) 2.1(1.5-3.2)
Median LDH Level IU/L (range) 196(145-445)
PBSC mobilization regimen
ESHAP 27
HD-CY 22
G-CSF alone 0
Others 6
MM indicates: multiple myeloma, NHL: non-hodgkin lymphoma, HL:
hodgkin lymphoma, HD-CY: high dose cyclophosphamide142
Using Hematopoietic Cell Transplantation Comorbidity
Index (HCT-CI) to Predict Autologous Transplant-Related
Toxicities in Elderly Patients Aged 65 or Older
Chang-Yi Yvonne Liu 1, D. Kathryn Tierney 2. 1 Hematology/
Oncology, Palo Alto Medical Foundation, Mountain View, CA;
2 Blood and Marrow Transplantation, Stanford University
Medical Center, Stanford, CA
Background: An HCT-CI score of 3 demonstrated signiﬁcant
differences in non-relapse mortality (NRM) and overall
survival independent from Karnofsky Performance Status
(KPS) in allogeneic HCT recipients. An HCT-CI score of 3 did
not predict NRM and survival in multiple myeloma (MM),
Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma
(NHL), but did predict signiﬁcant differences in the devel-
opment of grade 3-5 toxicities in NHL patients.
Purpose: Use of HCT-CI score to predict grade 3-5 toxicities
within 90 days post-autologous HCT in elderly patients.
Method: RetrospectivelyutilizedanHCT-CI scoreof3 topredict
grade 3-5 toxicities in autologous HCT patients  65 years in
a single HCT center in 2011. Outcome variables included
pulmonary (pneumonitisorﬁbrosis), gastrointestinal (diarrhea,
nausea ormucositis), neurologic (confusion), renal dysfunction
(increased creatinine), hepatic dysfunction (increased ALT/
AST), cardiovascular (decreased ejection fraction, and atrial or
ventricular arrythmias), fatigue and bone pain. Grading criteria
were based on the National Cancer Institute Common Termi-
nology Criteria Adverse Events version 4.0.
Results: The sample consisted of 37 autologous HCT recipi-
ents a mean of 67.4 years (range of 65-71), including 19
males (51.4%) and 18 females (48.6%) with the following
diagnoses MM (13), HL (1) NHL (21) and amyloidosis (2). Atthe time of transplant, 59.5% were not in complete remission.
KPS score was  80% in all patients and  90% in 33 (89.2%).
One patient expired 19 days post-HCT and two suffered
a relapse 55 and 107 days post-HCT, respectively. Each of
these three patients had HCT-CI scores 3. Utilizing HCT-CI
criteria, 23 (62.1%) had decreased pulmonary function, 6
(16.2%) had decreased cardiovascular function, 3 (8.1%) had
solid tumor history, and 3 (8.1%) had depression or anxiety.
Using an HCT-CI score of 3, 18 patients scoring  3
developed 44 grade 3-5 toxicities, while 19 patients with
a score < 3 developed 20 grade 3-5 toxicities (p ¼ .002).
ANCOVA multivariate analysis demonstrated that an HCT-CI
score of 3 can predict the number of grade 3-5 toxicities (p ¼
.044) independently from age, gender, KPS, diagnoses, and
pre-transplant disease status.
Conclusion: This retrospective study utilizing an HCT-CI
score of 3 predicted grade 3-5 toxicity in the ﬁrst 90 days
following HCT in elderly autologous HCT recipients inde-
pendent of KPS, diagnoses, disease status, age, and gender.
Thepredictive ability of theHCT-CI is superior toperformance
status. AddingHCT-CI to pre-HCTeligibility criteria for elderly
patients should be considered. Use of the HCT-CI may also be
utilized as part of pre-HCT counseling and education.143
Inﬂuence of Diabetes On Autologous Hematopoietic Stem
Cell Mobilization
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Recent experimental data in murine studies suggests that
hematopoietic stem cells (HSC) may not mobilize as well in
mice with diabetes (DM) compared to non-diabetic mice. We
performed a retrospective study of patients with and
without DM undergoing ﬁrst autologous stem cell mobili-
zation from 1/1/2009 to 1/1/2012 to compare efﬁciency of
mobilization and collection of CD34+ cells. Method of
mobilization was decided by the attending physician.
Chemotherapy and G-CSF were used if therapy or cytor-
eduction was necessary and, per institutional guideline,
cytokine only mobilization was G-CSF 10 ug/kg daily with
apheresis starting on day 5, and plerixafor 0.24 mg/kg was
added on day 4 if the peripheral blood CD34+ cells/ul was
< 15. A total of 343 pts underwent 362 attempts at collection
with 56 (15%) having type II DM. Failure to mobilize CD34
cells was deﬁned as never reaching 10 or greater peripheral
blood CD34+ cells/ul, or collecting less than 2 million CD34+
cells/kg. Both DM and non-DM pts required a median of 2
(range 1-4) days of apheresis for successful collection. The
mean total CD34+ cells/kg x 106 collected (std dev) was 6.12
(2.66) in DM pts vs 6.8 (3.58) in non-DM pts (p¼0.05). When
stratiﬁed by method of mobilization, the mean and median
total CD34+ cells collected were less, and the mean days of
apheresis were more in DM pts, but this did not reach
statistical signiﬁcance. Overall, 11/343 (3.2%) pts failed to
mobilize adequate CD34+cells and did not proceed to
autologous HSC transplant, with 4 of the 11 (36%) having DM.
Engraftment and day 100 transplant outcomes were not
different between pts with and without DM. In conclusion,
pts with DM may mobilize less CD34+ cells, but this appears
to be a small effect that is primarily overcome by current
methods of mobilization, with the majority of patients still
able to proceed to autologous HSC transplant. Larger studies
